Cadence Neuroscience

Key People

• Kent Leyde - Co-Founder, President, Chief Executive Officer & Board Member
• Doug Sheffield, Ph.D. - Co-Founder, Chief Scientific Officer & Board Member

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical device development and clinical studies.

The co-founders, Kent Leyde and Doug Sheffield, have significant experience in neural implant product development and clinical studies, providing a strong foundation for the company's endeavors.

Clinical Need

Aspect: Very Strong
Summary: The therapy addresses a significant unmet need in treating drug-resistant epilepsy.

Drug-resistant epilepsy affects a substantial patient population lacking effective treatment options, highlighting the strong clinical need for innovative therapies like those developed by Cadence Neuroscience.

Competition

Aspect: Somewhat crowded
Summary: The neuromodulation market has several players, but Cadence's unique approach offers differentiation.

The neuromodulation field includes various companies; however, Cadence's focus on chronic subthreshold cortical stimulation for epilepsy offers a novel approach that may distinguish it from competitors.

Technical Challenge

Aspect: Moderate
Summary: Developing and clinically validating neuromodulation therapies presents moderate technical challenges.

While developing neuromodulation therapies involves complexities, the experienced team at Cadence Neuroscience is well-equipped to address these challenges effectively.

Patent

Aspect: Strong
Summary: The company has a solid patent portfolio supporting its technology.

Cadence Neuroscience holds patents related to its neuromodulation therapy systems, providing intellectual property protection and potential market advantage.

Financing

Aspect: Well-funded
Summary: The company has secured significant funding to support its clinical and regulatory efforts.

With $41 million raised, including a $26 million Series B round, Cadence Neuroscience is well-capitalized to pursue pivotal clinical studies and regulatory approvals.

Regulatory

Aspect: Pivotal Trial
Summary: The company is preparing for pivotal clinical trials to seek regulatory approval.

Cadence Neuroscience plans to use its recent funding to complete pivotal clinical studies and pursue FDA clearance for its neuromodulation therapy.

Opportunity Rollup

Odds of Success

3.75

Peak Market Share

4.7

Segment CAGR

4.9%

Market Segment

Neurology Devices

Market Sub Segment

Neuromodulation Devices

Key Takeaway

Cadence Neuroscience, with its experienced team and innovative therapy for drug-resistant epilepsy, is well-positioned in a growing market, though it faces moderate competition and technical challenges.